Navigation Links
Tafamidis: Approval denotes proven added benefit
Date:9/17/2012

Tafamidis meglumine (trade name: Vyndaqel) was approved in November 2011 for the treatment of transthyretin amyloidosis in adults. This rare disorder ("orphan disease") is caused by a defective gene and is associated with progressive nerve damage (neurological degeneration) that tafamidis is supposed to delay. According to 35a SGB (Social Code Book) V, an added benefit is regarded as proven if a drug for a rare disease - known as an orphan drug - has been approved. The German Institute for Quality and Efficiency in Health Care (IQWiG) has assessed tafamidis at the request of the Federal Joint Committee (G-BA).

The scientific assessment by IQWiG has produced a hint of a positive effect of tafamidis on neurological degeneration.

Tafamidis compared with "best supportive care"

Transthyretin (TTR) is formed in the liver and is involved in the transport of the thyroid hormone, thyroxine. Mutations in the TTR gene can lead to transthyretin amyloidosis in which there is a build-up of an abnormally modified protein in various organs. These insoluble deposits result in a chronic disease that is associated with the progressive degeneration of the nervous system (polyneuropathy). In most patients, the transthyretin gene is modified at a particular site and this mutation is called "Val30Met". Tafamidis meglumine is approved for the treatment of transthyretin amyloidosis in adult patients with stage 1 neurological disorders to delay the progression of degeneration of peripheral nerves, e.g. in the arms and legs.

Treatment with tafamidis combined with "best supportive care" was compared with "best supportive care" alone. The term "best supportive care" means the therapy that provides the patient with the best possible individually optimized supportive treatment to alleviate symptoms and improve the quality of life, for instance the treatment of pain in polyneuropathy with other drugs (e.g. amitriptyline, gabapentin).

Positive effect in neurological disorders only limited

Only one of the two relevant studies (Fx-005) provided reliable data - and only for patients with a particular genetic defect (Val30Met). The second study (Fx1A-201) in adults with different genetic defects was not controlled, i.e. here the effect of tafamidis was not directly compared with another treatment. It remains unclear how the results of the reliable study can be applied to the patients with genetic defects other than Val30Met.

Assessment of the study data according to the methods of IQWiG produced a hint of a positive effect of tafamidis in respect of the progression of nerve damage. However the effect was only minor.

With regard to other patient-relevant outcomes (other symptoms and side effects, mortality, quality of life), the Institute was unable to identify any further statistically significant advantages or disadvantages of tafamidis compared with the comparator treatment.

G-BA decides on the extent of added benefit

The dossier assessment is part of the overall procedure for early benefit assessment conducted by the G-BA. After publication of the manufacturer's dossier and its assessment by IQWiG, the G-BA initiates a formal commenting procedure which provides further information and can result in a change to the benefit assessment. The G-BA then decides on the extent of the added benefit, thus completing the early benefit assessment.


'/>"/>

Contact: Dr. Anna-Sabine Ernst
presse@iqwig.de
49-221-356-850
Institute for Quality and Efficiency in Health Care
Source:Eurekalert

Related medicine news :

1. Tafamidis: Approval denotes proven added benefit
2. U.S. Bests Canada, Europe in Drug Approvals
3. Approval of Safer Alternative to Pradaxa Delayed by FDA
4. EP Global Communications, Inc. Achieves Shareholder Approval for Restructuring and Signs Definitive Restructuring Agreement
5. UW study plays pivotal role in todays FDA approval of HIV prevention drug
6. Cleveland Clinic Florida receives approval for transplant programs at Weston Facilities
7. Electronic Cigarettes Proven as One of the Most Effective Ways to Quit Smoking
8. Collagenase for Dupuytrens contracture: Added benefit not proven
9. New roadmap suggests proven routes to ending health disparities
10. Added benefit of linagliptin is not proven
11. Benefit of PET and PET/CT in ovarian cancer is not proven
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... ... March 22, 2017 , ... Sam & Associates Insurance ... planning, and related services to residents of the region, is embarking on a ... species and wild lands. , Endangered Species International is committed to ending the ...
(Date:3/22/2017)... ... March 22, 2017 , ... Donor Network West, the federally-designated ... Inc., announced the future opening of a CLIA certified dedicated laboratory in northern ... to determine the suitability of potential organ and tissue donors. This partnership ...
(Date:3/22/2017)... ... March 22, 2017 , ... An intensive search of the medical ... reports Leslie Norins, MD, PhD. He says investigating this possibility, is important ... virus and in new infections with HIV. , His findings appear on ...
(Date:3/22/2017)... ... March 22, 2017 , ... Intrinsic Imaging, LLC, an ... and operational excellence in oncology clinical trials, proudly announces today that it has ... non-small cell lung cancer and small cell lung cancer. , Throughout this trial, ...
(Date:3/22/2017)... ... March 22, 2017 , ... The Jim Shortridge ... families and business owners, is joining the Teen Recovery Solutions organization in a ... , A growing number of Oklahoma teens and adolescents face problems from drugs, ...
Breaking Medicine News(10 mins):
(Date:3/22/2017)... Hologic, Inc. (Nasdaq: HOLX ) ... Cynosure, Inc., a leader in medical aesthetics systems and ... "We are pleased to complete our acquisition of Cynosure, ... and the entire Cynosure team to achieve even ... market," said Steve MacMillan , Hologic,s Chairman, President ...
(Date:3/22/2017)... FinancialBuzz.com News Commentary ... is strongly contributing to job creation. A recent report ... for the cannabis industry, projects that by 2020, the ... million jobs for American workers. The legal cannabis market ... is projected to grow at a compound annual growth ...
(Date:3/22/2017)... 22, 2017   Upsher-Smith Laboratories, Inc . (Upsher-Smith) today ... mg, 50 mg and 75 mg, the generic equivalent to ... The clomipramine hydrochloride capsules market had U.S. sales ... 2016, according to IMS Health. ... "Upsher-Smith has long been recognized within ...
Breaking Medicine Technology: